Prognostic effect of immunohistochemically determined molecular subtypes in gastric cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Gastric cancer molecular subtypes identified by immunohistochemistry show different prognoses. While EBV-positive and MSI subtypes indicate poorer survival, further research is needed to optimize subtyping for clinical decisions.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Gastric cancer is a leading cause of cancer death globally.
- Recent advancements include molecular subtyping by TCGA and ACRG.
- Understanding these subtypes is crucial for targeted therapies.
Purpose Of The Study
- To classify gastric cancer patients into molecular subtypes using immunohistochemistry.
- To evaluate the prognostic significance of different molecular subtypes.
- To compare the utility of TCGA and ACRG classifications.
Main Methods
- A cohort of 283 gastric cancer patients was analyzed.
- Tumor tissue microarrays were immunostained for MSI markers, p53, E-cadherin, and EBV-encoded RNA (EBERISH).
- Univariate survival analysis was performed to assess disease-specific survival.
Main Results
- Epstein-Barr virus (EBV)-positive subtype showed the worst prognosis (HR 2.49).
- TCGA classification revealed worse survival for genetically stable (GS) and microsatellite instability (MSI) subtypes.
- ACRG classification indicated poorer prognoses for wild-type p53, MSI, and epithelial-mesenchymal transition (EMT) subtypes.
Conclusions
- Immunohistochemistry can identify prognostically distinct gastric cancer subtypes.
- This method is cost-effective and rapid, providing valuable clinical information.
- Further development is needed to determine the optimal molecular subtyping strategy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.